<DOC>
	<DOCNO>NCT01260779</DOCNO>
	<brief_summary>This compassionate use protocol provide expanded access investigational use PV-10 cancer patient eligible exist PV-10 clinical trial , comparable satisfactory approve alternative therapy , opinion investigator , may benefit PV-10 administration .</brief_summary>
	<brief_title>Expanded Access Protocol PV-10 Cutaneous Subcutaneous Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Age 18 year old , male female . 2 . Histologically cytologically confirm cancer comparable satisfactory approve alternative therapy specific cutaneous subcutaneous tumor . 3 . Performance Status : ECOG 02 . 4 . Life Expectancy : At least 6 month . 5 . Blood Chemistry : Creatinine ≤ 3 time upper limit normal ( ULN ) . Total bilirubin ≤ 3 time upper limit normal ( ULN ) . AST/ALT/ALP ≤ 5 time upper limit normal ( ULN ) . 6 . Thyroid Function Total T3 free T3 ( serum triiodothyronine ) , total T4 free T4 ( serum thyroxine ) THS ( serum thyrotropin ) ≤ grade 2 abnormality . 7 . Renal Function Subjects must adequate renal function opinion Investigator clinically significant renal impairment uncontrolled renal disease . 1 . Cancer patient eligible exist PV10 clinical trial . 2 . Certain photosensitize agent within 5 halflives prior PV10 administration . 3 . Concurrent Intercurrent Illness : Subjects uncontrolled diabetes extremity complication due diabetes . Subjects severe peripheral vascular disease . Subjects significant concurrent intercurrent illness , psychiatric disorder , alcohol chemical dependence would , opinion Investigator , compromise safety compliance interfere interpretation study result . Subjects uncontrolled thyroid disease , goiter , partial thyroidectomy , radioiodine surgicallytreated Graves ' hyperthyroidism cystic fibrosis . Subjects clinically significant acute unstable cardiovascular , ( stroke ) , renal , gastrointestinal , pulmonary , immunological ( exception presence hepatitis B virus ( HBV ) , viral hepatitis , cirrhosis ) , endocrine , central nervous system disorder . 4 . Pregnancy : Female subject pregnant lactating . Female subject positive serum ßHCG pregnancy test take within 7 day PV10 administration . Fertile subject use effective contraception . 5 . Investigational Agents : Subjects receive investigational agent within 4 week ( 5 halflives ) study administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>